Skip to main content
PMC home page
Thorax logoLink to Thorax
. 2005 Aug 5;60(10):842–847. doi: 10.1136/thx.2005.043943

Implications of reversibility testing on prevalence and risk factors for chronic obstructive pulmonary disease: a community study

A Johannessen 1, E Omenaas 1, P Bakke 1, A Gulsvik 1
PMCID: PMC1747202  PMID: 16085729

Abstract

Background: The Global Initiative for Obstructive Lung Disease (GOLD) has defined chronic obstructive pulmonary disease (COPD) as a post-bronchodilator ratio of forced expiratory volume in 1 second to forced vital capacity (FEV1/FVC) of <0.7. In the first general population based study to apply post-bronchodilator values, the prevalence and predictors of GOLD defined COPD were assessed and the implications of ß2 agonist reversibility testing examined.

Methods: Based on a random population sample, 2235 subjects (77%) aged 26–82 years performed spirometric tests before and 15 minutes after inhaling 0.3 mg salbutamol.

Results: The prevalence of GOLD defined COPD was 7.0% (95% confidence interval (CI) 5.9 to 8.0). This estimate was 27% lower than COPD defined without bronchodilatation. One percent of the population had severe or very severe COPD. Compared with women, men had 3.1 (95% CI 2.1 to 4.8) times higher odds for COPD. Subjects with a smoking history of more than 20 pack years had an odds ratio (OR) of 6.2 (95% CI 3.4 to 11.0) for COPD relative to never-smokers, while subjects older than 75 years had an OR of 18.0 (95% CI 9.2 to 35.0) relative to those below 45 years. Subjects with primary education only had an OR of 2.8 (95% CI 1.4 to 5.3) compared with those with university education. Subjects with body mass index (BMI) <20 kg/m2 were more likely than subjects with BMI 25–29.9 kg/m2 to have COPD (OR 2.4, 95% CI 1.1 to 5.3). The adjusted proportion of COPD attributable to smoking was 68%.

Conclusions: These results indicate that community programmes on prevention of COPD should focus on anti-smoking, nutritional aspects, and socioeconomic conditions. The effect of ß2 reversibility testing on prevalence estimates of COPD was substantial.

Full Text

The Full Text of this article is available as a PDF (88.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bakke P. S., Baste V., Hanoa R., Gulsvik A. Prevalence of obstructive lung disease in a general population: relation to occupational title and exposure to some airborne agents. Thorax. 1991 Dec;46(12):863–870. doi: 10.1136/thx.46.12.863. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bakke P. S., Hanoa R., Gulsvik A. Educational level and obstructive lung disease given smoking habits and occupational airborne exposure: a Norwegian community study. Am J Epidemiol. 1995 Jun 1;141(11):1080–1088. doi: 10.1093/oxfordjournals.aje.a117373. [DOI] [PubMed] [Google Scholar]
  3. Bakke P., Gulsvik A., Lilleng P., Overå O., Hanoa R., Eide G. E. Postal survey on airborne occupational exposure and respiratory disorders in Norway: causes and consequences of non-response. J Epidemiol Community Health. 1990 Dec;44(4):316–320. doi: 10.1136/jech.44.4.316. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Becklake M. R., Kauffmann F. Gender differences in airway behaviour over the human life span. Thorax. 1999 Dec;54(12):1119–1138. doi: 10.1136/thx.54.12.1119. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Blanc P. D., Eisner M. D., Trupin L., Yelin E. H., Katz P. P., Balmes J. R. The association between occupational factors and adverse health outcomes in chronic obstructive pulmonary disease. Occup Environ Med. 2004 Aug;61(8):661–667. doi: 10.1136/oem.2003.010058. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Calverley Peter M. A. The GOLD classification has advanced understanding of COPD. Am J Respir Crit Care Med. 2004 Aug 1;170(3):211–214. doi: 10.1164/rccm.2405008. [DOI] [PubMed] [Google Scholar]
  7. Celli B. R., Halbert R. J., Isonaka S., Schau B. Population impact of different definitions of airway obstruction. Eur Respir J. 2003 Aug;22(2):268–273. doi: 10.1183/09031936.03.00075102. [DOI] [PubMed] [Google Scholar]
  8. Celli B. R., MacNee W., ATS/ERS Task Force Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004 Jun;23(6):932–946. doi: 10.1183/09031936.04.00014304. [DOI] [PubMed] [Google Scholar]
  9. Eagan Tomas M. L., Eide Geir E., Gulsvik Amund, Bakke Per S. Nonresponse in a community cohort study: predictors and consequences for exposure-disease associations. J Clin Epidemiol. 2002 Aug;55(8):775–781. doi: 10.1016/s0895-4356(02)00431-6. [DOI] [PubMed] [Google Scholar]
  10. Eagan Tomas M. L., Gulsvik Amund, Eide Geir E., Bakke Per S. Occupational airborne exposure and the incidence of respiratory symptoms and asthma. Am J Respir Crit Care Med. 2002 Oct 1;166(7):933–938. doi: 10.1164/rccm.200203-238OC. [DOI] [PubMed] [Google Scholar]
  11. Fabbri L. M., Hurd S. S., GOLD Scientific Committee Global Strategy for the Diagnosis, Management and Prevention of COPD: 2003 update. Eur Respir J. 2003 Jul;22(1):1–2. doi: 10.1183/09031936.03.00063703. [DOI] [PubMed] [Google Scholar]
  12. Greenland S., Drescher K. Maximum likelihood estimation of the attributable fraction from logistic models. Biometrics. 1993 Sep;49(3):865–872. [PubMed] [Google Scholar]
  13. Guerra Stefano, Sherrill Duane L., Bobadilla Arnel, Martinez Fernando D., Barbee Robert A. The relation of body mass index to asthma, chronic bronchitis, and emphysema. Chest. 2002 Oct;122(4):1256–1263. doi: 10.1378/chest.122.4.1256. [DOI] [PubMed] [Google Scholar]
  14. Gulsvik A., Tosteson T., Bakke P., Humerfelt S., Weiss S. T., Speizer F. E. Expiratory and inspiratory forced vital capacity and one-second forced volume in asymptomatic never-smokers in Norway. Clin Physiol. 2001 Nov;21(6):648–660. doi: 10.1046/j.1365-2281.2001.00377.x. [DOI] [PubMed] [Google Scholar]
  15. Hardie J. A., Buist A. S., Vollmer W. M., Ellingsen I., Bakke P. S., Mørkve O. Risk of over-diagnosis of COPD in asymptomatic elderly never-smokers. Eur Respir J. 2002 Nov;20(5):1117–1122. doi: 10.1183/09031936.02.00023202. [DOI] [PubMed] [Google Scholar]
  16. Johannessen A., Omenaas E., Bakke P., Gulsvik A. Incidence of GOLD-defined chronic obstructive pulmonary disease in a general adult population. Int J Tuberc Lung Dis. 2005 Aug;9(8):926–932. [PubMed] [Google Scholar]
  17. Kornmann O., Beeh K. M., Beier J., Geis U. P., Ksoll M., Buhl R., Global Initiative for Obstructive Lung Disease Newly diagnosed chronic obstructive pulmonary disease. Clinical features and distribution of the novel stages of the Global Initiative for Obstructive Lung Disease. Respiration. 2003 Jan-Feb;70(1):67–75. doi: 10.1159/000068417. [DOI] [PubMed] [Google Scholar]
  18. Landbo C., Prescott E., Lange P., Vestbo J., Almdal T. P. Prognostic value of nutritional status in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1999 Dec;160(6):1856–1861. doi: 10.1164/ajrccm.160.6.9902115. [DOI] [PubMed] [Google Scholar]
  19. Lundbäck B., Lindberg A., Lindström M., Rönmark E., Jonsson A. C., Jönsson E., Larsson L. G., Andersson S., Sandström T., Larsson K. Not 15 but 50% of smokers develop COPD?--Report from the Obstructive Lung Disease in Northern Sweden Studies. Respir Med. 2003 Feb;97(2):115–122. doi: 10.1053/rmed.2003.1446. [DOI] [PubMed] [Google Scholar]
  20. Mannino D. M., Buist A. S., Petty T. L., Enright P. L., Redd S. C. Lung function and mortality in the United States: data from the First National Health and Nutrition Examination Survey follow up study. Thorax. 2003 May;58(5):388–393. doi: 10.1136/thorax.58.5.388. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Nelson S. B., Gardner R. M., Crapo R. O., Jensen R. L. Performance evaluation of contemporary spirometers. Chest. 1990 Feb;97(2):288–297. doi: 10.1378/chest.97.2.288. [DOI] [PubMed] [Google Scholar]
  22. Pauwels R. A., Buist A. S., Calverley P. M., Jenkins C. R., Hurd S. S., GOLD Scientific Committee Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med. 2001 Apr;163(5):1256–1276. doi: 10.1164/ajrccm.163.5.2101039. [DOI] [PubMed] [Google Scholar]
  23. Peña V. S., Miravitlles M., Gabriel R., Jiménez-Ruiz C. A., Villasante C., Masa J. F., Viejo J. L., Fernández-Fau L. Geographic variations in prevalence and underdiagnosis of COPD: results of the IBERPOC multicentre epidemiological study. Chest. 2000 Oct;118(4):981–989. doi: 10.1378/chest.118.4.981. [DOI] [PubMed] [Google Scholar]
  24. Prescott E., Lange P., Vestbo J. Socioeconomic status, lung function and admission to hospital for COPD: results from the Copenhagen City Heart Study. Eur Respir J. 1999 May;13(5):1109–1114. doi: 10.1034/j.1399-3003.1999.13e28.x. [DOI] [PubMed] [Google Scholar]
  25. Sterk P. J. Let's not forget: the GOLD criteria for COPD are based on post-bronchodilator FEV1. Eur Respir J. 2004 Apr;23(4):497–498. doi: 10.1183/09031936.04.00017104. [DOI] [PubMed] [Google Scholar]
  26. Vestbo Jørgen, Lange Peter. Can GOLD Stage 0 provide information of prognostic value in chronic obstructive pulmonary disease? Am J Respir Crit Care Med. 2002 Aug 1;166(3):329–332. doi: 10.1164/rccm.2112048. [DOI] [PubMed] [Google Scholar]
  27. de Marco R., Accordini S., Cerveri I., Corsico A., Sunyer J., Neukirch F., Künzli N., Leynaert B., Janson C., Gislason T. An international survey of chronic obstructive pulmonary disease in young adults according to GOLD stages. Thorax. 2004 Feb;59(2):120–125. doi: 10.1136/thorax.2003.011163. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES